Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 4, 2012, Pages 354-366

  Giovacchini, G ^a   Breeuwsma, A J ^b  

^a Stadtspital Triemli ^*  (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Choline; Prostatic neoplasms; Recurrence

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHOLINE C 11; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; TRACER; UNCLASSIFIED DRUG;

ACCURACY; AGE; ANDROGEN DEPRIVATION THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; EARLY DIAGNOSIS; HIGH RISK PATIENT; HORMONE RESISTANCE; HUMAN; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK FACTOR; TREATMENT FAILURE; WHOLE BODY IMAGING;

CHOLINE; HUMANS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT FAILURE;

EID: 84869794598     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2005. CA Cancer J Clin 2010;60:277-300.
2. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80. (Pubitemid 350166735)
3. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-54.
4. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-9. (Pubitemid 351296130)
5. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101-5. (Pubitemid 30434268)
6. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23. (Pubitemid 36132976)
7. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, DAmico AV, Dmochowski RR et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540-5. (Pubitemid 46054056)
8. Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol 2003;43:12-27. (Pubitemid 36134310)
9. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
10. Jacinto AA, Fede AB, Fagundes LA, Salvajoli JV, Castilho MS, Viani GA et al. Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy. Radiat Oncol 2007;2:8.
11. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 2004;58:1530-5. (Pubitemid 38438317)
12. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9. (Pubitemid 43779173)
13. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24:1868-76. (Pubitemid 46638985)
14. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-59. (Pubitemid 24145607)
15. Dotan ZA, Bianco FJ, Jr., Rabbani F, Eastham JA, Fearn P, Scher HI et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23:1962-8. (Pubitemid 46211375)
16. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507. (Pubitemid 29220858)
17. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011;52:81-9.
18. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003;61:607-11. (Pubitemid 36294200)
19. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-91. (Pubitemid 29480523)
20. Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist 2009;14:1070-82.
21. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009;39:396-407.
22. Giovacchini G, Chiacchio S, AlSharif A. Tumors of the genitourinary system. In: Strauss WH, Mariani G, Volterrani D, Larson SM, editors. Nuclear Oncology: Basic Principles and Clinical Applications. New York: Springer; 2012.
23. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 2001;45:27-37. (Pubitemid 32586339)
24. Even-Sapir E, Flusser G, Lerman H, Lievshitz G, Metser U. SPECT/multislice low-dose CT: a clinically relevant constituent in the imaging algorithm of nononcologic patients referred for bone scintigraphy. J Nucl Med 2007;48:319-24. (Pubitemid 47555360)
25. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996;47:225-31. (Pubitemid 26075278)
26. Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int 2004;93:680-8. (Pubitemid 38375788)
27. Kramer S, Gorich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997;70:995-9.
28. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2011 [Epub ahead of print].
29. Chen AP, Cunningham CH, Kurhanewicz J, Xu D, Hurd RE, Pauly JM et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006;24:825-32. (Pubitemid 44205376)
30. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004;231:379-85. (Pubitemid 38552892)
31. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;162:1322-8. (Pubitemid 29428572)
32. Tiguert R, Gheiler EL, Tefilli MV, Oskanian P, Banerjee M, Grignon DJ et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 1999;53:367-71. (Pubitemid 29063328)
33. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274-92. (Pubitemid 39365998)
34. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008;49:2031-41.
35. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5. (Pubitemid 28270113)
36. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-3.
37. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-603. (Pubitemid 32694969)
38. Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997;17:1455-60. (Pubitemid 27257633)
39. Muller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Senekowitsch-Schmidtke R. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging 2009;36:1434-42.
40. Al-Saeedi F, Smith T, Welch A. [Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay. Anticancer Res 2007;27:901-6. (Pubitemid 46586997)
41. Al-Saeedi F, Welch AE, Smith TA. [methyl-3H]Choline incorporation into MCF7 tumour cells: correlation with proliferation. Eur J Nucl Med Mol Imaging 2005;32:660-7. (Pubitemid 40897488)
42. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668-73. (Pubitemid 40897489)
43. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol 2004;31:859-65.
44. Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C]acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006;33:977-84. (Pubitemid 44791951)
45. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, Robertson CN et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110-7. (Pubitemid 32095708)
46. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-14. (Pubitemid 34016349)
47. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187-99. (Pubitemid 34151041)
48. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-9.
49. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002;4:267-73. (Pubitemid 35214587)
50. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-40. (Pubitemid 36323779)
51. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8.
52. Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42:25-30. (Pubitemid 36231688)
53. Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA et al. Detection of Local, Regional, and Distant Recurrence in Patients With PSA Relapse After External-Beam Radiotherapy Using (11)C-Choline Positron Emission Tomography. Int J Radiat Oncol Biol Phys 2010;77:160-4.
54. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L et al. [(11)C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:13-26.
55. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273-80. (Pubitemid 34640843)
56. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/mL? Mol Imaging Biol 2006;8:43-8. (Pubitemid 44193401)
57. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:301-9.
58. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al. The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23. (Pubitemid 350234152)
59. Vicini FA, Ziaja EL, Kestin LL, Brabbins DS, Stromberg JS, Gonzalez JA et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999;54:111-7. (Pubitemid 29323342)
60. Obek C, Lai S, Sadek S, Civantos F, Soloway MS. Age as a prognostic factor for disease recurrence after radical prostatectomy. Urology 1999;54:533-8. (Pubitemid 29407034)
61. Freedland SJ, Presti JC, Jr., Kane CJ, Aronson WJ, Terris MK, Dorey F et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urology 2004;63:518-22.
62. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394-400.
63. Giovacchini G, Picchio M, Garcia Parra R, Briganti A, Gianolli L, Montorsi F et al. PSA velocity vs. PSA doubling time for prediction of C-11 choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 2012;37:325-31.
64. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:1106-16.
65. 18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:271-82.
66. Schillaci O, Calabria F, Tavolozza M, Caracciolo CR, Agrò EF, Miano R et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced (18)F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging [In press].
67. Reske SN, Blumstein NM, Glatting G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9-17.
68. Rinnab L, Blumstein NM, Mottaghy FM, Hautmann RE, Kufer R, Hohl K et al. (11)C-Choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007;99:1421-6. (Pubitemid 47164799)
69. Boccon-Gibod L. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a European perspective. BJU Int 2007;99(Suppl 1):2-5. (Pubitemid 44952819)
70. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H et al. (18)F-choline and/or (11)C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (>1 ng/mL) after radical prostatectomy. BJU Int 2007;99:1415-20. (Pubitemid 47164795)
71. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C et al. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/mL? Eur J Nucl Med Mol Imaging 2011;38:55-63.
72. Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A et al. [(11)C]Choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010;184:938-43.
73. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011;59:51-60.
74. De Waele A, Van Binnebeek S, Mottaghy FM. Response assessment of hormonal therapy in prostate cancer by [11C]choline PET/CT. Clin Nucl Med 2010;35:701-3.
75. Nakashima J, Imai Y, Tachibana M, Baba S, Hiramatsu K, Murai M. Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging. Cancer 1997;80:237-41. (Pubitemid 27282317)
76. Swinnen JV, Verhoeven G. Androgens and the control of lipid metabolism in human prostate cancer cells. J Steroid Biochem Mol Biol 1998;65:191-8. (Pubitemid 28335606)
77. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001;46:49-57. (Pubitemid 32592138)
78. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 1998;58:3009-14. (Pubitemid 28335080)
79. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35:1065-73.
80. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253-63.
81. Richter JA, Rodriguez M, Rioja J, Penuelas I, Marti-Climent J, Garrastachu P et al. Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010;12:210-7.
82. Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M et al. Androgen deprivation therapy influences the uptake of (11)C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011;38:1985-9.
83. Giovacchini G. Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline? Eur J Nucl Med Mol Imaging 2011;38:1964-6.
84. Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging 2008;52:50-65. (Pubitemid 351351044)
85. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98. (Pubitemid 44885404)
86. Steiner C, Vees H, Zaidi H, Wissmeyer M, Berrebi O, Kossovsky MP et al. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin 2009;48:1-9; quiz N2-3.
87. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006;47:150-4. (Pubitemid 46768524)
88. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007;52:423-9. (Pubitemid 46963456)
89. Giovacchini G, Gajate AM, Messa C, Fazio F. Increased C-11 choline uptake in pagetic bone in a patient with coexisting skeletal metastases from prostate cancer. Clin Nucl Med 2008;33:797-8.
90. Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE et al. [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008;81:191-7.
91. Fallanca F, Giovacchini G, Picchio M, Bettinardi V, Messa C, Fazio F. Incidental detection by [(11)C]choline PET/CT of meningiomas in prostate cancer patients. Q J Nucl Med Mol Imaging 2009;53:417-21.
92. Castellucci P, Fuccio C, Marzola MC, Al-Nahhas A, Rubello D, Fanti S. Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer. Nucl Med Commun 2011;32:475-8.
93. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-8. (Pubitemid 40571106)
94. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC et al. Value of [11C]-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34(1):45-53. (Pubitemid 44885553)
95. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007;100:786-93. (Pubitemid 47360183)
96. Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009;27:619-25.
97. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 2010;24:485-92.